Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. USO
7. GOOGL
8. HOOD
9. ABBV
10. DFTX

Go back to Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations

Dynavax (DVAX) Misses Q3 EPS by 8c

November 5, 2018 4:05 PM EST

Dynavax (NASDAQ: DVAX) reported Q3 EPS of ($0.65), $0.08 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $1.46 million versus the consensus estimate of $3.75 million.

For earnings history and earnings-related data on Dynavax (DVAX) click here.

... More